Arrowhead Pharmaceuticals has sent an application to the New Zealand regulator seeking clearance to commence a Phase I/IIa trial of ARO-ALK7.

The employee received an aggregate of 5,330 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of January 1, 2025, subject to such ...

Experts highlighted that Pakistan is one of the leading countries for cousin marriages in the world, resulting in genetic ...

Found primarily in the aforementioned Great Bear Rainforest on Canada’s north and central coast, spirit bears – also referred ...

Heterozygous familial hypercholesterolemia was associated with increased type 2 diabetes risk, especially among those with obesity and statin use.

Lexeo Therapeutics, Inc. (LXEO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Mitochondrial DNA (mtDNA)-encoded RNA molecules undergo extensive processing to generate mature RNA, including removal of ...

Praluent is a prescription drug used for certain conditions, including high cholesterol. Find out about possible interactions ...

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...